



30th April 2013

Aurobindo Pharma receives USFDA Approval for Quinapril Tablets

Aurobindo Pharma Limited is pleased to announce that the company has received final approval from the US Food & Drug Administration (USFDA) to manufacture and Quinapril Tablets USP 5mg, 10mg, 20mg and 40mg (ANDA 202725).

Quinapril Tablets USP 5mg, 10mg, 20mg and 40mg is the generic equivalent of Pfizer Pharmaceuticals Ltd's Accupril® Tablets 5mg, 10mg, 20mg and 40mg respectively, indicated for the treatment of hypertension and falls under the Cardiovascular (CVS) therapeutic category. The market size of the product is estimated to be US\$49 Million for the twelve months ending September 2012 according to IMS.

The product has been approved out of Unit VII (SEZ) formulations facility in Hyderabad, India

Aurobindo now has a total of 188 ANDA approvals (161 Final approvals including 4 from Aurolife Pharma LLC and 27 Tentative approvals) from USFDA

About Aurobindo Pharma Limited:

Aurobindo Pharma Limited (www.aurobindo.com), headquartered at Hyderabad, India, manufactures generic pharmaceuticals and active pharmaceutical ingredients. The company's manufacturing facilities are approved by several leading regulatory agencies like US FDA, UK MHRA, WHO, Health Canada, MCC South Africa, ANVISA Brazil. The company's robust product portfolio is spread over 6 major therapeutic/product areas encompassing Antibiotics, Anti-Retrovirals, CVS, CNS, Gastroenterologicals, and Anti-Allergics, supported by an outstanding R&D set-up. The Company is marketing these products globally, in over 125 countries.

For further information, please contact:

Investor Relations
Aurobindo Pharma Limited
Reg Off: Plot No. 2, Maitrivihar, Ameerpet, Hyderabad
Phone: 040-66725000 / 66725401
Email: ir@aurobindo.com